Revelation Biosciences (REVB) Profit After Tax (2020 - 2026)

Revelation Biosciences (REVB) has reported Profit After Tax for 6 consecutive years, with -$2.5 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Profit After Tax fell 44.87% year-over-year to -$2.5 million; the TTM figure through Dec 2025 stood at -$8.9 million (up 40.8% YoY), while the FY2025 annual figure was -$8.9 million, up 40.82% from the prior year.
• Profit After Tax retreated to -$2.5 million in Q4 2025 per REVB's latest filing, from -$1.9 million in the prior quarter.
• Across five years, Profit After Tax topped out at $6.2 million in Q1 2023 and bottomed at -$8.4 million in Q2 2024.
• Historically, Profit After Tax has averaged -$2.3 million across 5 years, with a median of -$2.3 million in 2024.
• Annual changes were most pronounced in 2021 — Profit After Tax tumbled 350649.31% — and 2023, when it jumped 193.09%.
• Revelation Biosciences' Profit After Tax stood at -$3.9 million in 2021, then surged by 68.72% to -$1.2 million in 2022, then tumbled by 82.42% to -$2.2 million in 2023, then gained by 21.66% to -$1.7 million in 2024, then sank by 44.87% to -$2.5 million in 2025.
• Business Quant data shows REVB's Profit After Tax at -$2.5 million in Q4 2025, -$1.9 million in Q3 2025, and -$2.4 million in Q2 2025.